Trouble sleeping? Do you speak Spanish and identify as Hispanic or Latino/a? Dormir Mejor team is recruiting for our study testing a smartphone application that delivers cognitive behavioral treatment for insomnia (CBT-I) among Spanish-Speaking Latino/as. To participate, fill out a study interest form by following the link: https://tinyurl.com/sleepdm or…
Trouble sleeping? Do you Identify as Latino/a and speak Spanish? Dormir Mejor team is recruiting for our study that is testing a digital cognitive behavioral therapy treatment for insomnia (CBT-I) among Spanish-speaking Latinos using a phone application! You may be eligible if: identify as Latina/o, speak Spanish, are 18 years old or older, and have…
This study will test a computer-based behavioral intervention to decrease cocaine use. Those who fail to achieve cocaine abstinence after the first 4 weeks while receiving the behavioral treatment will continue the behavioral treatment and be randomly assigned to one of two groups (one group will receive Adderall-XR (MAS-ER) and the other group will receive…
This is a clinical research study designed to determine the safety and effectiveness of the TIVUS system, an investigational device used in the treatment of PAH. The TIVUS System is intended to treat patients with pulmonary artery hypertension by injuring the sympathetic nerves surrounding the pulmonary vasculature (denervation) using ultrasonic energy. The…
This study involves two infusions of either rituximab or placebo, two right heart catheterizations (6 months apart), and a variety of other clinical study procedures and exams.
The study is a two group outpatient study, one group receiving medications (Adderall-XR and topiramate) and one group receiving a placebo (inactive sugar pill). The study is looking at the safety and effectiveness of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine dependence. It is a 14-week trial that requires patients to attend visits 3…
The purpose of this study is to study the effects of a new study drug known as Riociguat in people diagnosed with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Patients will be in the study for approximately 26 weeks in which they will take the pill Riogciguat three times a day.